See more : Nippon Denko Co., Ltd. (5563.T) Income Statement Analysis – Financial Results
Complete financial analysis of Zogenix, Inc. (ZGNX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zogenix, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- FTS International, Inc. (FTSI) Income Statement Analysis – Financial Results
- Guilin Layn Natural Ingredients Corp. (002166.SZ) Income Statement Analysis – Financial Results
- Edelweiss Financial Services Limited (EDELWEISS.BO) Income Statement Analysis – Financial Results
- Barksdale Resources Corp. (BRO.V) Income Statement Analysis – Financial Results
- Nightcap Plc (NGHT.L) Income Statement Analysis – Financial Results
Zogenix, Inc. (ZGNX)
About Zogenix, Inc.
Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 81.69M | 13.64M | 3.65M | 0.00 | 9.82M | 28.85M | 27.18M | 40.53M | 33.01M | 44.33M | 37.58M | 23.44M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 4.83M | 542.00K | 0.00 | 0.00 | 10.73M | 22.47M | 22.70M | 31.88M | 22.48M | 20.85M | 20.50M | 13.69M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 76.86M | 13.10M | 3.65M | 0.00 | -908.00K | 6.38M | 4.48M | 8.65M | 10.53M | 23.48M | 17.08M | 9.75M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 94.08% | 96.03% | 100.00% | 0.00% | -9.25% | 22.12% | 16.49% | 21.35% | 31.89% | 52.96% | 45.45% | 41.60% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 142.66M | 138.00M | 115.64M | 100.93M | 67.45M | 41.84M | 27.86M | 18.94M | 12.81M | 21.41M | 33.04M | 28.64M | 21.44M | 33.91M | 24.33M | 4.90M |
| General & Administrative | 0.00 | 99.57M | 33.63M | 23.22M | 21.12M | 20.99M | 22.41M | 88.90M | 50.04M | 49.49M | 60.46M | 51.27M | 14.10M | 11.82M | 4.73M | 1.47M |
| Selling & Marketing | 0.00 | 0.00 | 27.17M | 15.73M | 4.76M | 6.00M | 3.94M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 148.52M | 99.57M | 60.79M | 38.95M | 25.89M | 27.00M | 26.35M | 88.90M | 50.04M | 49.49M | 60.46M | 51.27M | 14.10M | 11.82M | 4.73M | 1.47M |
| Other Expenses | 7.89M | 3.94M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -10.00K | 10.00K |
| Operating Expenses | 299.07M | 241.52M | 176.43M | 139.88M | 93.33M | 68.84M | 54.21M | 107.84M | 62.85M | 70.91M | 93.50M | 79.91M | 35.54M | 45.73M | 29.05M | 6.38M |
| Cost & Expenses | 303.90M | 242.06M | 176.43M | 139.88M | 104.06M | 91.30M | 76.91M | 139.71M | 85.33M | 91.76M | 114.00M | 93.60M | 35.54M | 45.73M | 29.05M | 6.38M |
| Interest Income | 659.00K | 2.89M | 9.80M | 7.17M | 1.09M | 443.00K | 0.00 | 20.00K | 18.00K | 53.00K | 37.00K | 5.00K | 10.00K | 696.00K | 0.00 | 0.00 |
| Interest Expense | 15.28M | 3.76M | 2.00K | 6.00K | 2.64M | 2.83M | 0.00 | 3.09M | 6.61M | 10.31M | 7.64M | 10.01M | 9.19M | 1.72M | 1.35M | 980.00K |
| Depreciation & Amortization | 9.46M | 5.47M | 1.27M | 155.00K | 425.00K | 1.40M | 1.62M | 1.63M | 1.81M | 1.60M | 1.58M | 1.43M | 5.31M | 1.10M | 410.00K | 1.96M |
| EBITDA | -202.58M | -217.58M | -418.23M | -123.75M | -123.75M | -66.43M | 11.86M | 13.39M | -72.44M | -35.47M | -74.68M | -62.11M | -31.39M | -42.75M | -25.92M | -4.42M |
| EBITDA Ratio | -247.98% | -1,594.84% | -11,464.72% | 0.00% | -1,260.03% | -230.25% | 43.65% | 33.03% | -219.44% | -80.02% | -198.75% | -264.96% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -212.03M | -247.72M | -429.82M | -141.18M | -119.94M | -72.69M | -47.73M | -20.04M | -53.19M | -47.43M | -76.42M | -70.16M | -35.54M | -45.73M | -29.05M | -6.38M |
| Operating Income Ratio | -259.56% | -1,815.71% | -11,782.37% | 0.00% | -1,221.22% | -251.94% | -175.58% | -49.44% | -161.13% | -107.00% | -203.39% | -299.29% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -15.28M | 20.91M | 10.32M | 17.46M | -6.09M | 3.05M | -9.88M | 28.71M | -27.66M | 50.00K | -7.49M | -3.39M | -1.17M | 1.18M | 1.37M | 980.00K |
| Income Before Tax | -227.31M | -226.81M | -419.50M | -123.72M | -126.02M | -69.63M | -57.61M | 8.67M | -80.86M | -47.38M | -83.91M | -73.55M | -36.71M | -44.55M | -27.68M | -5.40M |
| Income Before Tax Ratio | -278.26% | -1,662.45% | -11,499.53% | 0.00% | -1,283.19% | -241.37% | -211.92% | 21.39% | -244.93% | -106.89% | -223.31% | -313.77% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 105.00K | -17.43M | 10.32M | 17.47M | -3.44M | -948.00K | -15.90M | 84.00K | -21.05M | 5.00K | -9.00K | 10.00K | 8.02M | 2.90M | 2.72M | 0.00 |
| Net Income | -227.41M | -209.38M | -419.50M | -123.91M | -126.82M | -69.71M | 26.14M | 8.59M | -80.86M | -47.39M | -83.90M | -73.56M | -45.89M | -45.57M | -27.68M | -5.40M |
| Net Income Ratio | -278.39% | -1,534.73% | -11,499.53% | 0.00% | -1,291.28% | -241.62% | 96.18% | 21.19% | -244.93% | -106.90% | -223.29% | -313.81% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -4.24 | -3.90 | -9.74 | -3.27 | -4.65 | -2.81 | 1.22 | 0.48 | -5.96 | -4.71 | -15.72 | -141.03 | -36.50 | -272.06 | -395.43 | -108.00 |
| EPS Diluted | -4.24 | -3.90 | -9.74 | -3.27 | -4.65 | -2.81 | 1.22 | 0.47 | -5.96 | -4.71 | -15.72 | -141.03 | -36.50 | -272.06 | -395.43 | -108.00 |
| Weighted Avg Shares Out | 53.69M | 53.69M | 43.07M | 37.89M | 27.30M | 24.79M | 21.45M | 17.83M | 13.57M | 10.07M | 5.34M | 521.63K | 1.26M | 167.50K | 70.00K | 50.00K |
| Weighted Avg Shares Out (Dil) | 53.69M | 53.69M | 43.07M | 37.89M | 27.30M | 24.79M | 21.45M | 18.13M | 13.57M | 10.07M | 5.34M | 521.63K | 1.26M | 167.50K | 70.00K | 50.00K |
Zogenix Stock (ZGNX): Why The Price Went Up Substantially Today
The stock price of Zogenix, Inc. (NASDAQ: ZGNX) increased by over 60% pre-market today. This is why it happened.
UCB to Buy Epilepsy-Focused Zogenix In $1.9B Deal: See The Highlights
Belgian-based UCB SA (OTC: UCBJF) has agreed to buy Zogenix Inc (NASDAQ: ZGNX), a U.S. maker of drugs to treat seizures and rare diseases, for $1.9 billion, expanding its portfolio to treat epilepsy. Investors will get $26 in cash for every Zogenix share, plus a...
Zogenix To Present New FINTEPLA® (fenfluramine) Data at AES 2021
Data add to the growing body of evidence supporting the efficacy and safety profile of FINTEPLA for the treatment of Dravet syndrome Data add to the growing body of evidence supporting the efficacy and safety profile of FINTEPLA for the...
Why Are Zogenix's Shares Gaining Today?
The FDA has granted Priority Review to Zogenix Inc's (NASDAQ: ZGNX) supplemental marketing application seeking approval for Fintepla (fenfluramine) in Lennox-Gastaut syndrome (LGS) childhood-onset epilepsy. The agency's Prescription Drug User Fee Act (PDUFA) target action date is March 25, 2022.
4 of the Fastest-Growing Stocks on the Planet Through 2024
Wall Street projects aggregate sales growth of 509% to 3,324% for these stocks.
Zogenix, Inc. (ZGNX) CEO Dr. Stephen Farr on Q3 2021 Results - Earnings Call Transcript
Zogenix, Inc. (ZGNX) CEO Dr. Stephen Farr on Q3 2021 Results - Earnings Call Transcript
Recap: Zogenix Q3 Earnings
Zogenix (NASDAQ:ZGNX) reported its Q3 earnings results on Thursday, November 4, 2021 at 04:01 PM. Here's what investors need to know about the announcement.
Zogenix Reports Granting of Inducement Awards
EMERYVILLE, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX) today announced that the compensation committee of the company's board of directors granted inducement awards to thirty-four (34) new non-executive employees. The awards were made on October 15, 2021, under...
Zogenix, Inc.: Still Cautiously Optimistic
Today, we revisit biopharma name Zogenix, Inc. for the first time since early this year.
Zogenix's Fintepla Shows Long-Term Seizure Frequency Reductions In Childhood Epilepsy
Zogenix Inc (NASDAQ: ZGNX) has announced interim data from an ongoing 12-month Phase 3 open-label extension (OLE) study of Fintepla (fenfluramine) in Lennox-Gastaut syndrome (LGS). Data showed that fenfluramine oral solution led to a clinically meaningful and sustained reduction in drop seizures.
Source: https://incomestatements.info
Category: Stock Reports
What were Zogenix’s revenue and net loss in 2021?
Net loss for the second quarter ended June 30, 2021, was $58.9 million, or a net loss of $1.05 per share compared with a net loss of $53.3 million, or a net loss of $0.96 per share, in the second quarter ended June 30, 2020. The Company recorded $32.5 million in revenue for the six months ended June 30, 2021.